Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know (2022)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.pcad.2022.01.002
- Subjects: LIPOPROTEÍNAS; TOMADA DE DECISÃO; PRÁTICA PROFISSIONAL
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2022
- Source:
- Título do periódico: Progress in cardiovascular diseases
- ISSN: 0033-0620
- Volume/Número/Paginação/Ano: v. 73, p. 32-40, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
VIRANI, Salim S et al. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in cardiovascular diseases, v. 73, p. 32-40, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.pcad.2022.01.002. Acesso em: 31 maio 2024. -
APA
Virani, S. S., Koschinsky, M. L., Maher, L., Mehta, A., Orringer, C. E., Santos Filho, R. D. dos, et al. (2022). Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in cardiovascular diseases, 73, 32-40. doi:10.1016/j.pcad.2022.01.002 -
NLM
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos Filho RD dos, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know [Internet]. Progress in cardiovascular diseases. 2022 ; 73 32-40.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.pcad.2022.01.002 -
Vancouver
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos Filho RD dos, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know [Internet]. Progress in cardiovascular diseases. 2022 ; 73 32-40.[citado 2024 maio 31 ] Available from: https://doi.org/10.1016/j.pcad.2022.01.002 - Foi com muita satisfação que recebemos o convite dos ...[Apresentação]
- Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- Elevated uric acid, the metabolic syndrome and cardiovascular disease [Editorial]: cause, consequence, or just a not so innocent bystander?
- Lipid-lowering treatment for homozygous familial hypercholesterolaemia [Carta]
- Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
Informações sobre o DOI: 10.1016/j.pcad.2022.01.002 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
